Oasmia Pharmaceutical AB (OASM), a publicly-traded company that develops, manufactures, and sells cancer-treating drugs, is being investigated for potential violations of federal securities laws.
Oasmia Terminates Relationship With Executive Chairman
After market close on July 9, 2019, Oasmia announced that it had terminated its “engagement and cooperation” agreement with former executive chairman Julian Aleksov after a tax audit revealed missing money related to suspicious transactions between Oasmia and companies controlled by Aleksov and his former father-in-law.
The next day Oasmia stock closed down 13%, causing significant damage to shareholders.
Oasmia held its initial public offering in 2015 with Aegis Capital Corp and others helping the company raise about $8 million.
Recovering Money Lost With Oasmia Pharmaceutical AB (OASM) Stock
If you suffered losses with Oasmia stock or options, you may be able to recover some of your losses.
Silver Law Group represents the interests of investors who have been the victims of investment fraud. Our attorneys represent investors in class actions against issuers in state or federal court and investors in securities arbitration claims against Wall Street firms for stockbroker misconduct. Scott Silver is the chairman of the Securities and Financial Fraud Group of the American Association of Justice and represents investors nationwide in securities investment fraud cases. Please contact Scott Silver of the Silver Law Group for a free consultation at firstname.lastname@example.org or toll free at (800) 975-4345.